Revlimid (lenalidomide) - Important Safety Information from Celgene as approved by the Irish Medicines Board
12 April 2011
Important Safety Information communication from Celgene regarding the potential risk of second primary malignancies in patients treated with Revlimid (lenalidomide).
Important Safety Information - Revlimid